Real‐world experience of immune checkpoint inhibitors in patients with solid tumours in the Top End of the Northern Territory, Australia from 2016 to 2021: a retrospective observational cohort study

Author:

Miller Abigail R.1ORCID,Balino Aries2,Tun Min Sandy2,Downton Teesha2ORCID,Karanth Narayan V.2,Backen Alison3,Charakidis Michail24

Affiliation:

1. Cancer Service The Queen Elizabeth Hospital, Central Adelaide Local Health Network Adelaide South Australia Australia

2. Medical Oncology Royal Darwin Hospital Darwin Northern Territory Australia

3. Medical Oncology The Christie NHS Foundation Trust Manchester UK

4. Faculty of Health Charles Darwin University Darwin Northern Territory Australia

Abstract

AbstractBackgroundUse of immune checkpoint inhibitors is growing, but clinical trial data may not apply to Indigenous patients or patients living in remote areas.AimsTo provide real‐world incidence of immune‐related adverse events (irAE) in the Top End of the Northern Territory and compare incidence between demographic subgroups.MethodsThis retrospective, observational, cohort study collected data from electronic records of patients living in the Top End with solid organ cancer treated with immunotherapy between January 2016 and December 2021. The primary outcome was cumulative incidence of any‐grade and severe irAE. Secondary outcomes were overall survival, treatment duration and reason for treatment discontinuation.ResultsTwo hundred and twenty‐six patients received immunotherapy. Forty‐eight (21%) lived in a remote or very remote area, and 36 (16%) were Indigenous. Cumulative incidence of any‐grade irAE was 54% (122/226 patients); incidence of severe irAE was 26% (59/226 patients). Rates were similar between Indigenous and non‐Indigenous patients of any‐grade (42% vs 56%, P = 0.11) and severe (11% vs 18%, P = 0.29) irAE. However, Indigenous patients had shorter treatment duration, more frequently discontinued treatment due to patient preference and appeared to have shorter median overall survival than non‐Indigenous patients (17.1 vs 30.4 months; hazard ratio (HR) = 1.5, 95% confidence interval (CI) = 0.92–2.66). There was no difference in mortality between remote and urban patients (median overall survival 27.5 vs 30.2 months; HR = 1.1, 95% CI = 0.7–1.7).ConclusionsRates of irAE in our cohort are comparable to those in the published literature. There was no significant difference in any‐grade or severe irAE incidence observed between Indigenous and non‐Indigenous patients.

Publisher

Wiley

Reference20 articles.

1. Australian Institute of Health and Welfare.Cancer in Australia 2021. (AIHW Cat. No. CAN 144; Cancer series no. 133). Canberra: AIHW; 2021 [Cited 2023 Sep 8]. Available from URL:https://www.aihw.gov.au/getmedia/0ea708eb-dd6e-4499-9080-1cc7b5990e64/aihw-can-144.pdf?v=20230605165731&inline=true#page125.

2. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

3. Immune-related adverse events of immune checkpoint inhibitors: a review

4. Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials

5. Improving recruitment to clinical trials for regional and rural cancer patients through a regionally based clinical trials network

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3